サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790424

米国の細胞・遺伝子治療受託研究機関の市場規模、シェア、動向分析レポート：タイプ別、サービス別、適応症別、モダリティ別、セグメント別予測、2025年～2033年

U.S. Cell & Gene Therapy Contract Research Organizations Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Preclinical, Clinical), By Service, By Indication, By Modality, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.45円
米国の細胞・遺伝子治療受託研究機関の市場規模、シェア、動向分析レポート：タイプ別、サービス別、適応症別、モダリティ別、セグメント別予測、2025年～2033年
出版日: 2025年07月28日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向：

米国の細胞・遺伝子治療受託研究機関の市場規模は、2024年に20億9,000万米ドルと推計され、2033年には48億6,000万米ドルに達し、2025年から2033年までのCAGRは9.91%で成長すると予測されています。

市場の成長は、細胞および遺伝子ベースの治療薬の複雑化、CGTにおける臨床試験量の増加、バイオテクノロジー企業によるアウトソーシングの増加、規制の複雑化などによる。

市場は、科学的革新、規制の変更、スポンサーのニーズの進化などによるコラボレーションの拡大が牽引しています。自己細胞治療、遺伝子編集介入、in vivoウイルスベクターベースの治療など、先進的な治療法の数は増加の一途をたどっており、多くの場合、高度に調整された前臨床・臨床開発プログラムを必要とする治験段階や臨床段階に達しています。中小規模のバイオテクノロジー企業の大半は、このような治療、特に希少疾患や超希少疾患をターゲットとする治療に対する複雑な臨床、規制、生物学的分析の要求に対応するための社内インフラを欠いています。このギャップが、トランスレーショナルバイオロジー、GMPに準拠したサンプル管理、免疫原性試験などのニッチな専門知識を持つCROへの需要を煽っています。

さらに、スポンサーがCROと統合的なパートナーシップを結んで固定的な運営コストを削減し、拡張性を高める戦略的アウトソーシングモデルの増加も、市場成長を促進する要因の一つです。CAR-TやAAVベースの治療など、ロジスティクスや患者固有の複雑性が高い治療法では、治験依頼者、臨床施設、規制機関の間で綿密な調整が必要となるため、治験依頼者は科学的な深みと業務上の敏捷性の両方をもたらすCROと契約することになります。産学連携の拡大、希少疾患の臨床試験を支援する政府のイニシアティブ、細胞・遺伝子治療新興企業へのベンチャーキャピタル流入の増加は、CROの需要をさらに増大させています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の細胞・遺伝子治療受託研究機関市場：変数、動向、範囲

  • 市場系統の見通し
  • 米国の細胞・遺伝子治療受託研究機関の市場力学
  • 技術的情勢
  • 価格モデル分析
  • 米国の細胞・遺伝子治療受託研究機関市場：分析ツール

第4章 米国の細胞・遺伝子治療受託研究機関市場：タイプ別の推定・動向分析

  • セグメントダッシュボード
  • 米国の細胞・遺伝子治療受託研究機関市場の変動分析：タイプ別
  • 米国の細胞・遺伝子治療受託研究機関市場の規模・動向分析：タイプ別、2021年～2033年
  • 創薬
    • ターゲット検証
    • リード識別
    • リード最適化
  • 前臨床
  • 臨床
    • フェーズI
    • フェーズII
    • フェーズIII
    • フェーズIV

第5章 米国の細胞・遺伝子治療受託研究機関市場：サービス別の推定・動向分析

  • セグメントダッシュボード
  • 米国の細胞・遺伝子治療受託研究機関市場の変動分析：サービス別
  • 米国の細胞・遺伝子治療受託研究機関市場の規模・動向分析：サービス別、2021年～2033年
  • プロジェクトおよび臨床試験管理
  • 規制戦略
  • データ管理とメディカルライティング
  • 臨床モニタリング
  • 品質管理/GMPコンプライアンス
  • 生物統計学と安全性モニタリング
  • 患者と施設の募集
  • 技術移転
  • その他

第6章 米国の細胞・遺伝子治療受託研究機関市場：適応症別の推定・動向分析

  • セグメントダッシュボード
  • 米国の細胞・遺伝子治療受託研究機関市場の変動分析：適応症別
  • 米国の細胞・遺伝子治療受託研究機関市場の規模・動向分析：適応症別、2021年～2033年
  • 腫瘍学
  • 中枢神経系疾患
  • 感染症
  • 臨床モニタリング
  • 免疫疾患
  • 心血管疾患
  • 呼吸器疾患
  • 糖尿病
  • 眼科
  • 疼痛管理
  • その他

第7章 米国の細胞・遺伝子治療受託研究機関市場：モダリティ別の推定・動向分析

  • セグメントダッシュボード
  • 米国の細胞・遺伝子治療受託研究機関市場の変動分析：モダリティ別
  • 米国の細胞・遺伝子治療受託研究機関市場の規模・動向分析：モダリティ別、2021年～2033年
  • 細胞治療
  • 遺伝子治療
  • 遺伝子組み換え細胞療法

第8章 競合情勢

  • 企業分類
    • マーケットリーダー
    • 新興企業
  • 企業市場シェア/評価分析、2024年
  • 企業プロファイル
    • Altasciences
    • Allucent
    • LabCorp
    • Linical
    • Medpace
    • Thermo Fisher Scientific Inc.
    • Precision Medicine Group, LLC.
    • QPS Holdings
    • Syneos Health
    • ICON plc
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 U.S. cell & gene therapy contract research organizations market estimates and forecasts, by type, 2021 - 2033 (USD Million)
  • Table 3 U.S. cell & gene therapy contract research organizations market estimates and forecasts, by service, 2021 - 2033 (USD Million)
  • Table 4 U.S. cell & gene therapy contract research organizations market estimates and forecasts, by indication, 2021 - 2033 (USD Million)
  • Table 5 U.S. cell & gene therapy contract research organizations market estimates and forecasts, by modality, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. cell & gene therapy contract research organizations market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Segment snapshot
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Parent market outlook, 2024 (USD Million)
  • Fig. 17 Ancillary market outlook, 2024 (USD Million)
  • Fig. 18 U.S. Cell & Gene Therapy Contract Research Organizations market dynamics
  • Fig. 19 Total R&D drug pipeline size, 2021 - 2024
  • Fig. 20 Total drug pipeline by development phase, 2024
  • Fig. 21 Porter's five forces analysis
  • Fig. 22 PESTEL analysis
  • Fig. 23 U.S. cell & gene therapy contract research organizations market type outlook: Segment dashboard
  • Fig. 24 U.S. cell & gene therapy contract research organizations market, by type segment: Market share, 2025 & 2033
  • Fig. 25 Drug discovery market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Preclinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Target validation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Lead identification market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Lead optimization market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. cell & gene therapy contract research organizations market phase outlook: Segment dashboard
  • Fig. 32 U.S. cell & gene therapy contract research organizations market, by phase segment: Market share, 2024 & 2033
  • Fig. 33 Phase I market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Phase II market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Phase III market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Phase IV market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. cell & gene therapy contract research organizations market service outlook: Segment dashboard
  • Fig. 38 Cell & gene therapy contract research organizations market, by service segment: Market share, 2024 & 2033
  • Fig. 39 Project & clinical trial management market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Regulatory strategy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Data management & medical writing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Clinical monitoring market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Quality management / GMP compliance market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Biostatistics & safety monitoring market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Patient & site recruitment market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Technology transfer market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 U.S. cell & gene therapy contract research organizations market indication outlook: Segment dashboard
  • Fig. 49 U.S. cell & gene therapy contract research organizations market, by Indication segment: Market share, 2024 & 2033
  • Fig. 50 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 CNS disorders market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Immunological disorders market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Cardiovascular diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Respiratory diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Ophthalmology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Pain management market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 U.S. cell & gene therapy contract research organizations market modality outlook: Segment dashboard
  • Fig. 61 U.S. cell & gene therapy contract research organizations market, by Modality segment: Market share, 2024 & 2033
  • Fig. 62 U.S. Cell-based therapies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Gene therapies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Gene-modified cell therapies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Market participant categorization
  • Fig. 66 Heat map analysis
目次
Product Code: GVR-4-68040-688-5

Market Size & Trends:

The U.S. cell & gene therapy contract research organizations market size was estimated at USD 2.09 billion in 2024 and is projected to reach USD 4.86 billion by 2033, growing at a CAGR of 9.91% from 2025 to 2033. The growth of the market is due to growing complexity of cell- and gene-based therapeutics, rising clinical trial volume in CGT, increased outsourcing by biotech firms, regulatory complexity, among others.

The market is being driven by growing collaboration among scientific innovation, regulatory changes, and evolving sponsor needs. A growing number of advanced therapies-including autologous cell therapies, gene editing interventions, and in vivo viral vector-based treatments-are reaching investigational and clinical stages, often requiring highly tailored preclinical and clinical development programs. Most small-to-midsize biotech firms lack the internal infrastructure to navigate the complex clinical, regulatory, and bioanalytical demands of such therapies, especially those targeting rare or ultra-rare conditions. This gap fuels demand for CROs with niche expertise in translational biology, GMP-compliant sample management, and immunogenicity testing.

Furthermore, an increase in strategic outsourcing models, where sponsors form integrated partnerships with CROs to reduce fixed operational costs and increase scalability, is also one of the factors driving the market growth. The high logistical and patient-specific complexity of therapies such as CAR-T or AAV-based interventions necessitates deep coordination between trial sponsors, clinical sites, and regulatory bodies, prompting sponsors to engage CROs that bring both scientific depth and operational agility. The expansion of academic-industry partnerships, government initiatives supporting rare disease trials, and growing venture capital inflows into cell and gene therapy startups further amplify CRO demand.

U.S. Cell & Gene Therapy Contract Research Organizations Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. cell & gene therapy contract research organizations market report based on type, phase, service, indication, and modality:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Drug Discovery
    • Target Validation
    • Lead Identification
    • Lead Optimization
  • Preclinical
  • Clinical
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Project & Clinical Trial Management
  • Regulatory Strategy
  • Data Management & Medical Writing
  • Clinical Monitoring
  • Quality Management / GMP Compliance
  • Biostatistics & Safety Monitoring
  • Patient & Site Recruitment
  • Technology Transfer
  • Others
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • CNS Disorders
  • Infectious Diseases
  • Immunological Disorders
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Diabetes
  • Ophthalmology
  • Pain Management
  • Others
  • Modality Outlook (Revenue, USD Million, 2021 - 2033)
  • Cell-Based Therapies
  • Gene Therapies
  • Gene-Modified Cell Therapies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Cell & Gene Therapy Contract Research Organizations Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. U.S. Cell & Gene Therapy Contract Research Organizations Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. U.S. Cell & Gene Therapy Contract Research Organizations Market: Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis

Chapter 4. U.S. Cell & Gene Therapy Contract Research Organizations Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Cell & Gene Therapy Contract Research Organizations Market Type Movement Analysis
  • 4.3. U.S. Cell & Gene Therapy Contract Research Organizations Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Drug Discovery
    • 4.4.1. Drug Discovery Market Estimates and Forecasts, 2021 - 2033 (USD million)
    • 4.4.2. Target Validation
      • 4.4.2.1. Target Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Lead Identification
      • 4.4.3.1. Lead Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Lead Optimization
      • 4.4.4.1. Lead Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Preclinical
    • 4.5.1. Preclinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Clinical
    • 4.6.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Phase I
      • 4.6.2.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Phase II
      • 4.6.3.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.4. Phase III
      • 4.6.4.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.6.5. Phase IV
      • 4.6.5.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Cell & Gene Therapy Contract Research Organizations Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Cell & Gene Therapy Contract Research Organizations Market Service Movement Analysis
  • 5.3. U.S. Cell & Gene Therapy Contract Research Organizations Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
  • 5.4. Project & Clinical Trial Management
    • 5.4.1. Project & Clinical Trial Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Regulatory Strategy
    • 5.5.1. Regulatory Strategy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Data Management & Medical Writing
    • 5.6.1. Data Management & Medical Writing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Clinical Monitoring
    • 5.7.1. Clinical Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Quality Management / GMP Compliance
    • 5.8.1. Quality Management / GMP Compliance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Biostatistics & Safety Monitoring
    • 5.9.1. Biostatistics & Safety Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.10. Patient & Site Recruitment
    • 5.10.1. Patient & Site Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.11. Technology Transfer
    • 5.11.1. Technology Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.12. Others
    • 5.12.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Cell & Gene Therapy Contract Research Organizations Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Cell & Gene Therapy Contract Research Organizations Market Indication Movement Analysis
  • 6.3. U.S. Cell & Gene Therapy Contract Research Organizations Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. CNS Disorders
    • 6.5.1. CNS Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Infectious Diseases
    • 6.6.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Clinical Monitoring
    • 6.7.1. Clinical Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Immunological Disorders
    • 6.8.1. Immunological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Cardiovascular Diseases
    • 6.9.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Respiratory Diseases
    • 6.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Diabetes
    • 6.11.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12. Ophthalmology
    • 6.12.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.13. Pain Management
    • 6.13.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.14. Others
    • 6.14.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Cell & Gene Therapy Contract Research Organizations Market: Modality Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Cell & Gene Therapy Contract Research Organizations Market Modality Movement Analysis
  • 7.3. U.S. Cell & Gene Therapy Contract Research Organizations Market Size & Trend Analysis, by Modality, 2021 to 2033 (USD Million)
  • 7.4. Cell-Based Therapies
    • 7.4.1. Cell-Based Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Gene Therapies
    • 7.5.1. Gene Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Gene-Modified Cell Therapies
    • 7.6.1. Gene-Modified Cell Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Share/Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Altasciences
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Allucent
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. LabCorp
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Linical
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Medpace
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Thermo Fisher Scientific Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Precision Medicine Group, LLC.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. QPS Holdings
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Syneos Health
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. ICON plc
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives